Ocular Therapeutix (OCUL)
NASDAQ:OCUL

Ocular Therapeutix Stock Analysis & Ratings

Ocular Therapeutix Stock Analysis Overview

Smart Score
2
Underperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Ocular Therapeutix stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

OCUL

OCUL Stock Stats

Previous Close$5.63
Open$5.78
Bid5.08 x 100
Ask7.1 x 100
Today’s Range$5.42 - $5.78
52-Week Range$5.18 - $21.48
Volume583.82K
Average Volume1.01M
Market Cap$419.82M
Beta1.71
P/E Ratio-2.8
EPS-1.94
Earnings DateMar 10, 2022

Company Description

Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Sector
Healthcare
Industry
Biotechnology
CEO
Antony C. Mattessich
Employees
181
Website
http://www.ocutx.com
ISIN
US67576A1007
Address
24 Crosby Drive, Bedford, MA, 01730, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

OCUL FAQ

What was Ocular Therapeutix’s price range in the past 12 months?
Ocular Therapeutix lowest stock price was $5.18 and its highest was $21.48 in the past 12 months.
    What is Ocular Therapeutix’s market cap?
    Ocular Therapeutix’s market cap is $419.82M.
      What is Ocular Therapeutix’s price target?
      The average price target for Ocular Therapeutix is $22.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $30.00 ,the lowest forecast is $14.00. The average price target represents 301.46% Increase from the current price of $5.48.
        What do analysts say about Ocular Therapeutix?
        Ocular Therapeutix’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
          When is Ocular Therapeutix’s upcoming earnings report date?
          Ocular Therapeutix’s upcoming earnings report date is Mar 10, 2022 which is in 42 days.
            How were Ocular Therapeutix’s earnings last quarter?
            Ocular Therapeutix released its earnings results on Nov 08, 2021. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.26 by $0.29.
              Is Ocular Therapeutix overvalued?
              According to Wall Street analysts Ocular Therapeutix’s price is currently Undervalued.
                Does Ocular Therapeutix pay dividends?
                Ocular Therapeutix does not currently pay dividends.
                What is Ocular Therapeutix’s EPS estimate?
                Ocular Therapeutix’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Ocular Therapeutix have?
                Ocular Therapeutix has 76,610,000 shares outstanding.
                  What happened to Ocular Therapeutix’s price movement after its last earnings report?
                  Ocular Therapeutix reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.26. Following the earnings report the stock price went up 9.469%.
                    Which hedge fund is a major shareholder of Ocular Therapeutix?
                    Among the largest hedge funds holding Ocular Therapeutix’s share is RA Capital Management. It holds Ocular Therapeutix’s shares valued at 8M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis